



Agilis Biotherapeutics Discusses Gene Therapy for Angelman Syndrome, Co-Sponsors FAST-Global Summit

Agilis Leads Funding Support for Outcome Measures for AS

Chicago, Ill., December 4, 2015--Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Dr. Jodi Cook, Vice President Operations, and Dr. Gregory Robinson, Chief Scientific Officer, were distinguished presenters at the Foundation for Angelman Syndrome Therapeutics' (FAST) Annual Global Summit on Angelman Syndrome. Agilis co-sponsored the research fundraising event in Chicago, Ill. where Dr. Robinson highlighted Agilis' ongoing research for Angelman syndrome gene therapy in collaboration with Edwin Weeber, Ph.D., Professor, Molecular Pharmacology and Physiology, Chief Scientific Officer, USF Health Byrd Alzheimer's Institute and Director, Neurobiology of Learning and Memory Laboratory at the University of South Florida. Dr. Weeber has published his scientific findings on a potential gene therapy approach for Angelman syndrome using UBE3A gene replacement.

"Agilis is honored to co-sponsor and participate in the FAST Global Summit for the treatment of Angelman syndrome," said Dr. Robinson.

Dr. Cook presented an overview of Agilis' gene-therapy drug-development plan and the vision for the outcome measures consortium. Dr. Cook has organized key stakeholders to investigate, develop, and collect outcome data for AS to be used to further all types of future treatments. Agilis provided initial funding to launch the outcome measures consortium.

"Agilis is excited to partner with The Foundation for Angelman Syndrome Therapeutics to initiate an outcome measures consortium and further the Company's commitment to expediting a treatment for AS," said Dr. Cook.

FAST is an organization of families and professionals dedicated to finding a cure for Angelman syndrome and related disorders through the funding of an aggressive research agenda, education, and advocacy. The FAST Annual Global Summit brings together leaders in the fields of Angelman syndrome research education and medical care as well as more than 600 parents of those affected by this disorder. FAST's grants and fellowship programs encourage research aimed at finding a treatment for Angelman syndrome.

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's ataxia, Angelman syndrome and Fragile X syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 patients living with Angelman syndrome in the US. Fragile X syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilibio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information, contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809